Alnylam Pharmaceuticals Appoints New Chief Medical Officer
Ticker: ALNY · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1178670
Sentiment: neutral
Topics: executive-appointment, compensation, leadership
Related Tickers: ALNY
TL;DR
Alnylam names Dr. Blake Wilson as new CMO, effective June 12, $500k salary.
AI Summary
Alnylam Pharmaceuticals, Inc. announced on June 18, 2025, that its Board of Directors appointed Dr. Blake R. Wilson as Chief Medical Officer, effective June 12, 2025. Dr. Wilson will receive an annual base salary of $500,000 and will be eligible for equity awards and other compensation as per the company's standard executive compensation policies.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could influence the company's R&D strategy and clinical trial progression.
Risk Assessment
Risk Level: low — This filing reports on a routine executive appointment and compensation, which typically carries low risk.
Key Numbers
- $500,000 — Annual Base Salary (For the new Chief Medical Officer, Dr. Blake R. Wilson.)
Key Players & Entities
- Alnylam Pharmaceuticals, Inc. (company) — Company filing the report
- Dr. Blake R. Wilson (person) — Newly appointed Chief Medical Officer
- $500,000 (dollar_amount) — Annual base salary for the new CMO
- June 12, 2025 (date) — Effective date of appointment
- June 18, 2025 (date) — Date of report
FAQ
Who has been appointed as the new Chief Medical Officer at Alnylam Pharmaceuticals?
Dr. Blake R. Wilson has been appointed as the new Chief Medical Officer.
When was the appointment of the new Chief Medical Officer effective?
The appointment was effective as of June 12, 2025.
What is the annual base salary for the new Chief Medical Officer?
The annual base salary for Dr. Blake R. Wilson is $500,000.
What other compensation is Dr. Wilson eligible for?
Dr. Wilson is eligible for equity awards and other compensation as per the company's standard executive compensation policies.
What is the filing date of this 8-K report?
The filing date of this 8-K report is June 18, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 by Dr. Blake R. Wilson regarding ALNYLAM PHARMACEUTICALS, INC. (ALNY).